Further to the announcement on 2 January 2025 (the "2.4 Announcement”) and the update on the potential combination of Poolbeg ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 7 and set a price target of $10.00.

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

Drugmakers have greeted 2025, implementing price hikes for 583 products within the first two days of the new year, according ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.